Merck + Co., Inc.

Otto D Hensens

Jerrold M Liesch

Deborah L Zink

Cheryl D Schwartz

Robert E Schwartz

Leeyuan Huang

Kenneth E Wilson

Raymond S Chang

Yiu-kuen T Lam

Richard L Monaghan

Robert A Giacobbe

John G Ondeyka

Gerald F Bills

Janet C Onishi

Sheldon B Zimmerman

Sagrario M Del Val

Richard W Burg

Lawrence R Koupal

Seok H Lee

Anne W Dombrowski

Maria T Diez

Isabel Martin

Dan A Ostlind

Jon D Polishook

Carol F Wichmann

Gregory L Helms

James E Flor

George D Hartman

Roger M Freidinger

Robert L Smith

Wasyl Halczenko

Gerald E Stokker

Ta J Lee

Fernando Pelaez

George M Garrity

Sebastian Hernandez

Edward S Inamine

Maria L Garcia

Henry Joshua

Michael A Goetz

Prakash S Masurekar

Owen B McManus

David F Sesin

Eugene L Dulaney

James D Bergstrom

E Tracy Jones

August J Kempf

Maria I Fernandez

Walter Rozdilsky

Frank L VanMiddlesworth

Maria B Lopez

David R Houck

Rosalind G Jenkins

James A Milligan

Thomas C Hallada

Richard G Endris

Cheryl Deriso

H Boyd Woodruff

Joseph Dunn, Jr

Mark G Bock

Robert T Goegelman

Raymond F White

Russell B Lingham

Dennis M Schmatz

Paul S Anderson

Gregory J Kaczorowski

Louis Kaplan

Douglas J Pettibone

John R Thompson

Suzanne M Mandala

Guy H Harris

Francisca Vicente

James E Curotto

Claude Dufresne

Kevin M Byrne

Michael D Greenspan

Yu L Kong

Sandra A Morris

Angela Basilio

Hans E Huber

Lucille J Cole

Angeles Cabello

Sarah J Dreikorn

Robert P Borris

Michael J Salvatore, Jr

Sagrario Mochales

Athanasios Tsipouras

Siobhan Stevens-Miles

Ruth S Sykes

Leeyan Huang

Maria T Matas

Denis R Patrick

Susan L Raghoobar

Russel B Lingham

M Dolores Vilella Amils

Marina Mojena Sanchez

Annie Z Zhao

Reamer, Robert A

Livia Kelemen

A compound represented by the formula I is disclosed: ##STR1## or a pharmaceutically acceptable salt or hydrate thereof. The compound has inhibitory activity against the oncoprotein Raf. Also included are pharmaceutical compositions, methods of treating cancer, cultures of the producing fungal microorganism and methods of fermentative production of the compound.

Bis-aryl ethers, compositions containing such compounds and methods of

There are disclosed novel compounds having the formula ##STR1## which exhibit antifungal activity.

Antifungal agents

There are disclosed novel compounds which are derived from the fermentation of a strain of Nodulisporium sp. The compounds are highly potent ectoparasiticidal, antiparasitic and, insecticidal gents.

Antiparasitic agents

The present invention relates to compounds of the formula: ##STR1## and the pharmaceutically acceptable salts thereof which are useful as potassium channel antagonists, particularly Maxi-K channel antagonists, and thus useful in treating Alzheimer's Disease and other cognitive disorders. This invention is also related to a method of making the compound of formula (I).

Indole diterpene alkaloid compounds

Novel peptidyl derivatives of formula I are found to be potent inhibitors of interleukin-1.beta. converting enzyme (ICE). Compounds of formula I may be useful in the treatment of inflammatory or immune-based diseases of the lung and airways; central nervous system and surrounding membranes; the eyes and ears; joints, bones, and connective tissues; cardiovascular system including the pericardium; the gastrointestinal and urogenital systems; the skin and mucosal membranes. Compounds of formula I are also useful in treating the complications of infection (e.g., gram negative shock) and tumors in which IL 1 functions as an autocrine growth factor or as a mediator of cachexia. ##STR1##

Gamma-pyrone-3-acetic acid as an inhibitor or interleukin-1 .beta.

The present invention relates to novel potassium channel agonists which are useful in activating the calcium activated Maxi-K potassium channel in mammalian neuronal and smooth muscle tissue. The claimed compounds are of the general formula: ##STR1## In addition, a novel microbiological process for producing the claimed compounds is described.

Biologically active compounds

A new antibiotic cyclic lipopeptide having the formula ##STR1## wherein R is H or OH and a method of producing is described. The agent has very high activity against human pathogens and is of very low mammalian toxicity.

Antibiotic agent

A new antibiotic cyclic lipopeptide having the formula ##STR1## wherein R is H SEQ ID NO:1 or OH SEQ ID NO:2 and a method of producing is described. The agent has very high activity against human pathogens and is of very low mammalian toxicity.

Compounds having the formula ##STR1## wherein R and R.sup.1 may be H or COCH.sub.3 provided that when R.sup.1 is COCH.sub.3, R is COCH.sub.3 are described.

Antibiotic agents

Substituted hexahydrobenzopyran derivatives of the Formulae A, B, or C are useful as angiotensin II antagonists: ##STR1##

Substituted hexahydrobenzopyran derivatives as angiotensin II antagonists

An antibiotic agent produced by the cultivation of Zalerion arboricola which is a cyclic lipopeptide with very high activity against human pathogens and of very low mammalian toxicity is described. Its production and isolation are also described.

Antibiotic cyclopeptide fermentation product

Pharmaceutical compositions containing Virginiamycin M.sub.1 having the Formula: ##STR1## and Virginiamycin M.sub.1 analogs having the Formulae I-IV: ##STR2## are disclosed which are useful in the treatment of panic disorder or anxiety disorder.

Fermentation analogs of Virginiamycin M.sub.1 to treat panic and anxiety

An antiviral agent produced by Hypoxylon fragiforme and having the structure: ##STR1## is described. The product has high activity as an HIV protease enzyme inhibitor and is useful in the treatment of diseases in which control of HIV protease activity is desirable.

Antiviral agent

A phospholipid having the formula ##STR1## is described. The compound has antifungal properties.

Antifungal agent

Growing community of inventors

Red Bank, NJ, United States of America

Otto D Hensens